Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess
Background Endocrine therapy is central to the treatment of hormone receptor-positive breast cancer, yet hepatobiliary adverse-event reporting across endocrine agents remains incompletely characterized. We evaluated hepatobiliary reporting patterns and disproportionality signals using FAERS, with VigiAccess as a supple...